|
1) Filipovich AH, Weisdorf D, Pavletic S, et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant. 2005; 11: 945-56
|
|
|
|
2) Storb R, Deeg HJ, Pepe M, et al. Methotrexate and cyclosporine versus cyclosporine alone for prophylaxis of graft-versus-host disease in patients given HLA-identical marrow grafts for leukemia: long-term follow-up of a controlled trial. Blood. 1989; 73: 1729-34
|
|
|
|
|
|
3) Deeg HJ, Lin D, Leisenring W, et al. Cyclosporine or cyclosporine plus methylprednisolone for prophylaxis of graft-versus-host disease: a prospective, randomized trial. Blood. 1997; 89: 3880-7
|
|
|
|
|
|
4) Pavletic SZ, Carter SL, Kernan NA, et al. Influence of T-cell depletion on chronic graft-versus-host disease: results of a multicenter randomized trial in unrelated marrow donor transplantation. Blood. 2005; 106: 3308-13
|
|
|
|
|
|
5) Parkman R. Clonal analysis of murine graft- vs. -host disease. I. Phenotypic and functional analysis of T lymphocyte clones. J Immunol. 1986; 136: 3543-8
|
|
|
|
|
|
6) Molldrem JJ, Lee PP, Wang C, et al. Evidence that specific T lymphocytes may participate in the elimination of chronic myelogenous leukemia. Nat Med. 2000; 6: 1018-23
|
|
|
|
|
|
7) Rezvani K, Yong AS, Savani BN, et al. Graft-versus-leukemia effects associated with detectable Wilms tumor-1 specific T lymphocytes following allogeneic stem cell transplantation for acute lymphoblastic leukemia (ALL). Blood. 2007; 110: 1924-32
|
|
|
|
|
|
8) Fukushi N, Arase H, Wang B, et al. Thymus: a direct target tissue in graft-versus-host reaction after allogeneic bone marrow tranpslantation that results in abrogation of induction of self-tolerance. Proc Natl Acad Sci U S A. 1990; 87: 6301-5
|
|
|
|
|
|
9) Hollander GA, Widmer B, Burakoff SJ. Loss of normal thymic repertoire selection and persistence of autoreactive T cells in graft vs. host disease. J Immunol. 1994; 152: 1609-17
|
|
|
|
|
|
10) Tivol E, Komorowski R, Drobyski WR. Emergent autoimmunity in graft-versus-host disease. Blood. 2005; 105: 4885-91
|
|
|
|
|
|
11) Hess AD, Horowitz L, Beschomer WE, et al. Development of graft-versus-host disease-like syndrome in cyclosporine treated rats after syngeneic bone marrow transplantation. I. Development of cytotoxic T lymphocytes with apparent polyclonal anti-Ia specificity, including autoreactivity. J Exp Med. 1985; 161: 718-30
|
|
|
|
|
|
12) Teshima T, Reddy P, Liu C, et al. Impaired thymic negative selection causes autoimmune graft-versus-host disease. Blood. 2003; 102: 429-35
|
|
|
|
|
|
13) Korngold R, Sprent J. Lethal graft-versus-host disease after bone marrow transplantation across minor histocompatibility barriers in mice. Prevention by removing mature T-cells from marrow. J Exp Med. 1978; 148: 1687-98
|
|
|
|
|
|
14) Wagner JE, Thompson JS, Carter SL, et al. Effect of graft-versus-host disease prophylaxis on 3-year disease-free survival in recipients of unrelated donor bone marrow (T-cell Depletion Trial): a multi-centre, randomised phase II-III trial. Lancet. 2005; 366: 733-41
|
|
|
|
|
|
15) Anderson BE, McNiff JM, Jain D, et al. Distinct roles for donor- and host-derived antigen-presenting cells and costimulatory molecules in murine chronic graft-versus-host disease: requirements depend on target organ. Blood. 2005; 105: 2227-34
|
|
|
|
|
|
16) Douek DC, Vescio RA, Betts MR, et al. Assessment of thymic output in adults after haematopoietic stem-cell transplantation and prediction of T-cell reconstitution. Lancet. 2000; 355: 1875-81
|
|
|
|
|
|
17) Lewin SR, Heller G, Zhang L, et al. Direct evidence for new T-cell generation by patients after either T-cell-depleted or unmodified allogeneic hematopoietic stem cell transplantations. Blood. 2002; 100: 2235-42
|
|
|
|
|
|
18) Sakoda Y, Hashimoto D, Asakura S, et al. Donor-derived thymic-dependent T cells cause chronic graft-versus-host disease. Blood. 2007; 109: 1756-64
|
|
|
|
|
|
19) Shlomchik WD, Couzens MS, Tang CB, et al. Prevention of graft versus host disease by inactivation of host antigen-presenting cells. Science. 1999; 285: 412-5
|
|
|
|
|
|
20) Duffner UA, Maeda Y, Cooke KR, et al. Host dendritic cells alone are sufficient to initiate acute graft-versus-host disease. J Immunol. 2004; 172: 7393-8
|
|
|
|
|
|
21) Zhang Y, Louboutin JP, Zhu J, et al. Preterminal host dendritic cells in irradiated mice prime CD8＋ T cell-mediated acute graft-versus-host disease. J Clin Invest. 2002; 109: 1335-44
|
|
|
|
|
|
22) Merad M, Hoffmann P, Ranheim E, et al. Depletion of host Langerhans cells before transplantation of donor alloreactive T cells prevents skin graft-versus-host disease. Nat Med. 2004; 10: 510-7
|
|
|
|
|
|
23) Zhang Y, McCormick LL, Desai SR, et al. Murine sclerodermatous graft-versus-host disease, a model for human scleroderma: cutaneous cytokines, chemokines, and immune cell activation. J Immunol. 2002; 168: 3088-98
|
|
|
|
|
|
24) Banovic T, MacDonald KP, Morris ES, et al. TGF-beta in allogeneic stem cell transplantation: friend or foe？ Blood. 2005; 106: 2206-14
|
|
|
|
|
|
25) Zhang C, Todorov I, Zhang Z, et al. Donor CD4＋ T and B cells in transplants induce chronic graft-versus-host disease with autoimmune manifestations. Blood. 2006; 107: 2993-3001
|
|
|
|
|
|
26) Kebriaei P, Saliba RM, Ma C, et al. Allogeneic hematopoietic stem cell transplantation after rituximab-containing myeloablative preparative regimen for acute lymphoblastic leukemia. Bone Marrow Transplant. 2006; 38: 203-9
|
|
|
|
|
|
27) Miklos DB, Kim HT, Zorn E, et al. Antibody response to DBY minor histocompatibility antigen is induced after allogeneic stem cell transplantation and in healthy female donors. Blood. 2004; 103: 353-9
|
|
|
|
|
|
28) Miklos DB, Kim HT, Miller KH, et al. Antibody responses to H-Y minor histocompatibility antigens correlate with chronic graft-versus-host disease and disease remission. Blood. 2005; 105: 2973-8
|
|
|
|
|
|
29) Svegliati S, Olivieri A, Campelli N, et al. Stimulatory autoantibodies to PDGF receptor in patients with extensive chronic graft-versus-host disease. Blood. 2007; 110: 237-41
|
|
|
|
|
|
30) Distler JH, Jungel A, Huber LC, et al. Imatinib mesylate reduces production of extracellular matrix and prevents development of experimental dermal fibrosis. Arthritis Rheum. 2007; 56: 311-22
|
|
|
|
|
|
31) Ratanatharathorn V, Carson E, Reynolds C, et al. Anti-CD20 chimeric monoclonal antibody treatment of refractory immune-mediated thrombocytopenia in a patient with chronic graft-versus-host disease. Ann Intern Med. 2000; 133: 275-9
|
|
|
|
|
|
32) Cutler C, Miklos D, Kim HT, et al. Rituximab for steroid-refractory chronic graft-versus-host disease. Blood. 2006; 108: 756-62
|
|
|
|
|
|
33) Tsoi MS, Storb R, Dobbs S, et al. Specific suppressor cells in graft-versus-host tolerance of HLA-identical marrow transplantation. Nature. 1981; 292: 355-7
|
|
|
|
|
|
34) Bacchetta R, Bigler M, Touraine JL, et al. High levels of interleukin 10 production in vivo are associated with tolerance in SCID patients transplanted with HLA mismatched hematopoietic stem cells. J Exp Med. 1994; 179: 493-502
|
|
|
|
|
|
35) Zorn E, Kim HT, Lee SJ, et al. Reduced frequency of FOXP3＋ CD4＋CD25＋ regulatory T cells in patients with chronic graft-versus-host disease. Blood. 2005; 106: 2903-11
|
|
|
|
|
|
36) Anderson BE, McNiff JM, Matte C, et al. Recipient CD4＋ T cells that survive irradiation regulate chronic graft-versus-host disease. Blood. 2004; 104: 1565-73
|
|
|
|
|
|
37) Zeiser R, Nguyen VH, Beilhack A, et al. Inhibition of CD4＋CD25＋ regulatory T-cell function by calcineurin-dependent interleukin-2 production. Blood. 2006; 108: 390-9
|
|
|
|
|
|
38) Coenen JJ, Koenen HJ, van Rijssen E, et al. Rapamycin, not cyclosporine, permits thymic generation and peripheral preservation of CD4＋ CD25＋ FoxP3＋ T cells. Bone Marrow Transplant. 2007; 39: 537-45
|
|
|
|
|
|
39) Rezvani K, Mielke S, Ahmadzadeh M, et al. High donor FOXP3-positive regulatory T-cell (Treg) content is associated with a low risk of GVHD following HLA-matched allogeneic SCT. Blood. 2006; 108: 1291-7
|
|
|
|
|